New ADHD pill for kids shows promise in Late-Stage trial
NCT ID NCT06359899
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an oral capsule called AK0901 (AZSTARYS) in children aged 6 to 12 with attention deficit hyperactivity disorder (ADHD). The trial compares the drug against a placebo to see if it reduces ADHD symptoms like inattention and hyperactivity. Researchers measure symptom changes using a standard rating scale over several weeks. The goal is to determine if AK0901 is a safe and effective treatment option for this age group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AK0901 (AZSTARYS, a combination of serdexmethylphenidate and dexmethylphenidate)
What this could lead to
If successful, this could provide a new oral medication option to help manage ADHD symptoms in children aged 6-12.
What could go wrong
This is a relatively small Phase 3 trial, and results may not confirm effectiveness or safety for all children. Common ADHD medication risks include appetite loss, sleep problems, and mood changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADHD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing anding hospital capital medical university
Beijing, Beijing Municipality, China
-
Peking university sixth hospital
Beijing, Beijing Municipality, China